Quantcast

Industry news that matters to you.  Learn more

So My Brain Amyloid Level is “Elevated”—What Does That Mean?

Testing drugs to prevent or delay the onset of Alzheimer’s dementia and using them in the clinic will mean identifying and informing adults who have a higher risk of Alzheimer’s but are still cognitively normal. A new study from the Perelman School of Medicine at the University of Pennsylvania has shed light on how seniors cope with such information.

New Study: Videssa Breast Blood Test Can Effectively Rule Out Breast Cancer, Regardless of Breast Density

A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer by Provista Diagnostics, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue. Nearly half of all women in the U.S. have dense breast tissue.

Tyme Identifies Potential Method and Biomarker for Converting Malignant Tumors to Inert Calcified Mass

Tyme Technologies, Inc. (Nasdaq: TYME), a biotechnology company using cellular metabolism and oxidative stress to develop cancer therapeutics, today announced it has identified a mechanism and related biomarker that the Company believes could potentiate the calcification of tumors. During clinical evaluation of the Company’s lead product candidate, it was observed that subsequent to SM-88 therapy some lytic bone lesions converted to benign sclerotic bone. Following further examination, the Company believes it has isolated the cause of this conversion and developed a treatment method that can be used in combination with SM-88 to cause calcification of tumors with a particular biomarker. The Company has conducted a small number of tests in canine osteosarcoma and observed positive results, including a rapid ossification of tumors.

Immunovia Signs Major Autoimmune Biomarker Discovery Collaboration with Linkoping University

Immunovia announced today the signing of a major research collaboration on discovery of diagnostic biomarkers for autoimmune diseases with the Faculty of Medicine and Health Sciences, Linkoping University. The collaboration aims to accelerate the development of a new generation of diagnostic tests based on Immunovia’s leading IMMray™ antibody array platform.

What, Where and How: Exploring Disease Predisposition to Deliver Personalized Medicine

Geneticists from the University of Geneva have taken an important step towards true predictive medicine. Exploring the links between diseases and tissue-specific gene activity, they have been able to build a model that constitutes a first step towards the identification of specific sequences in the non-coding genome signalling their pathogenicity in the context of a specific disease. In a second study, they went even further by associating particular disease risks – including schizophrenia, cardiovascular disease and diabetes – to the variability of genome activity in various cell types, with surprising results. Their discoveries, which can be read in two articles published in Nature Genetics, may very well revolutionize how each one of us, depending on our genome, manage our health.